5Q With David R.P. Almeida, MD, MBA, PhD

David R.P. Almeida, MD, MBA, PhD, is a vitreoretinal surgeon at VitreoRetinal Surgery, PA, in Minneapolis, Minn.

 

1. How do you prepare for an unusual surgery case?

Planning is key. I prepare by deciphering what factors make the case challenging or unique and then plan to address these factors with the techniques that I know will produce the best outcomes. Intraoperatively, I stick to my plan, realizing that the time for action has arrived. Tough cases sometimes haunt surgeons, but I have come to appreciate that the last case cannot be done over and all that matters now is the next case.

2. Tell us how your PhD in pharmaceutical sciences gives you a different perspective on challenges in medical retina.

I approach many vitreoretinal disease states from a therapeutics design vantage point. This helps me to target the endpoint I am trying to achieve. Currently, in the sphere of medical retina, I believe we are limited in our therapeutics. I agree that we have more options than ever, but I feel that a lot of medical retina diseases have myriad relevant targets that will benefit from multiple modality treatment.

3. Does your MBA have applications in private practice, or is it more useful in a complex hospital system?

My MBA training allowed me to discover management guru Peter Drucker, whose model for effective decision-making includes asking questions such as: What is this all about? What is pertinent here? And, what is the key to the situation? I use this schematic every day, and I am thankful for his work on management by objectives. Specifically, I think my MBA is more applicable to private practice and other corporate models that value efficiency. I wish complex hospital systems and academic centers emphasized efficiency to a greater extent.

4. How do you begin a conversation about disease management with a diabetic patient who presents with diabetic macular edema?

I am a big believer in multiple modality treatment and synergy between different mechanisms of action. The well-studied pharmacodynamics concept of combination drug mechanisms of action in oncology and chemotherapy literature shows that certain synergistic drug combinations may act as a more potent version of a single drug. Consequently, I usually describe the options available (eg, anti-VEGF agents, corticosteroids, focal laser) and illustrate how I combine them over the course of therapy. I always stress the need for optimized systemic factors as well.

5. Your children have very cool names: Maximus, Leonardo, and Paloma. Tell us one interesting characteristic about each child.

My wife Jasmine and I thought long about each of the names of our children. Maximus was named after the film Gladiator, and his knowledge of dinosaurs is incredible. Once, before I left for a meeting in Alberta, he asked if I would bring him back an Edmontosaurus, as this is where they were first found (near Edmonton). We named Leonardo after Da Vinci because I have always loved Da Vinci’s Vitruvian Man. Leo has the best dance moves in the toddler scene. Paloma means dove in Spanish. She is our baby girl, and, given the fascination my wife and I have with Pablo Picasso’s Dove of Peace, this was the perfect name for her peaceful and enlightening smile. n

 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Karen Roman
Editor-in-Chief
484-581-1827
kroman@bmctoday.com

Janet Burk
Publisher
214-394-3551
jburk@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.